NPCE241115P7500
- 0.57
- 0.000.00%
NeuroPace Newsroom
Earnings Preview: NeuroPace to Report Financial Results Post-market on November 12
Express News | Neuropace Announces FDA Submission of Three-Year Data From Post-Approval Study of the Rns System in Focal Epilepsy
NeuroPace Announces FDA Submission of Three-Year Data From Post-Approval Study of the RNS System in Focal Epilepsy
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
NeuroPace (NPCE) Gets a Buy From Lake Street
Press Release: NeuroPace Strengthens Management Team With Two Key Appointments
NeuroPace to Participate in Upcoming Healthcare Conferences in September
NeuroPace Second Quarter 2024 Earnings: Beats Expectations
Earnings Release: Here's Why Analysts Cut Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$14.57
A Quick Look at Today's Ratings for NeuroPace(NPCE.US), With a Forecast Between $8 to $20
Express News | Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15
Express News | Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
NeuroPace Is Maintained at Overweight by Wells Fargo
NeuroPace Analyst Ratings
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15
Earnings Call Summary | NeuroPace(NPCE.US) Q2 2024 Earnings Conference
Express News | Neuropace, Inc. : Wells Fargo Cuts Target Price to $15 From $20
Microelectronic Medical Implants Market Report 2024-2029, With Profiles of Leading Players, Including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro
Express News | Neuropace Inc : JP Morgan Cuts Target Price to $9 From $17